
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Raltegravir Potassium
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Midas Pharma
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Coripharma and Midas Have Entered into an Exclusive Licensing Partnership
Details : Corifarma and Midas entered into an exclusive out-licensing cooperation for the European territory. The respective product, Raltegravir, can be launched in the EU in 2023 as a generic and is used in treatment of HIV/AIDS.
Product Name : Raltegravir-Generic
Product Type : Miscellaneous
Upfront Cash : Undisclosed
September 23, 2020
Lead Product(s) : Raltegravir Potassium
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Midas Pharma
Deal Size : Undisclosed
Deal Type : Licensing Agreement
